SearchDictionaryMobileLogin

Haemophilus influenzae HibTITER protein

Subscribe to Selected New Research on Haemophilus influenzae HibTITER protein
8  relevant articles (0 outcomes, 3 trials/studies) found for this Bio-Agent

Description: type b capsular polysaccharide of Hib-vaccine is conjugated to CRM 197

Also Known As:
HibTITER protein, Haemophilus influenzae; CRM197-Hib protein, Haemophilus influenzae; HIB capsular polysaccharide-mutant diphtheria toxin conjugate protein, Haemophilus influenzae; Haemophilus influenzae type b oligosaccharide vaccine-CRM 197 conjugate; HbOC protein, Haemophilus influenzae; Hib-Oligo-CRM197 protein, Haemophilus influenzae; Hib-titer protein, Haemophilus influenzae; PRP-CRM vaccine, Haemophilus influenzae; HibTITER

Bio-Agent Context: Research Results

-
Amino Acids, Peptides, and Proteins
-
Proteins: 58433
-
Bacterial Proteins: 166
*
Haemophilus influenzae HibTITER protein: 8
-
Complex Mixtures: 314
-
Biological Products
-
Vaccines: 15360
-
Bacterial Vaccines: 332
-
Haemophilus Vaccines: 24
*
Haemophilus influenzae HibTITER protein: 8

Related Diseases

1. Diphtheria
2. Tetanus
3. Whooping Cough (Pertussis)
05/01/1997 - "Immunogenicity of Haemophilus influenzae b conjugate vaccine (HibTITER) and safety of HibTITER and a combination vaccine of diphtheria, tetanus, pertussis and HibTITER in infants two months of age: a preliminary report."
01/01/2004 - "METHODS: In total, 331 babies were immunised with either Vaxem Hib (N = 167) or HibTITER (N = 164) vaccine at 6, 10 and 14 weeks of age, in parallel with oral polio, diphtheriatetanus-pertussis and hepatitis B vaccines. "
09/01/1998 - "Immunogenicity and safety of Haemophilus influenzae type b conjugate vaccine (HibTITER) and a combination vaccine of diphtheria, tetanus, pertussis and HibTITER (TETRAMUNE) in two-month-old infants."
05/01/1999 - "The immunogenic responses and local reactions to four Haemophilus influenzae type b (Hib) conjugate vaccines licensed for primary immunisation (Hiberix, ActHib, Pedvax, HibTITER) when administered concomitantly but in the opposite thigh with a candidate diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus vaccine were studied in 549 healthy infants at 3, 4.5 and 6 months of age. "
09/01/1999 - "OBJECTIVES: The objectives of this study were (1) to determine the safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate (PNCRM7) vaccine in infants and (2) to determine the effect of concurrent hepatitis B immunization during the primary series and the effect of concurrent diphtheria and tetanus toxoid and acellular pertussis [DTaP (ACEL-IMUNE)] and conjugate CRM197 Haemophilus influenzae type b [HbOC (HibTITER) immunization at time of the booster dose on the safety and immunogenicity of PNCRM7and these other concurrently administered vaccines. "
Order ALL the reference details at left...
4. Hepatitis B
5. Poliomyelitis (Polio)

Related Drugs and Biologics

1. Pertussis Vaccine
2. Haemophilus influenzae type b polysaccharide vaccine (HIB-vaccine)
3. CRM197 (non-toxic variant of diphtheria toxin)
4. Diphtheria-Tetanus-acellular Pertussis Vaccines (Tripedia)
5. Vaccines
6. Tetanus Toxoid (Vaccine, Tetanus)
7. heptavalent pneumococcal conjugate vaccine (Prevnar)
8. diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine (TriHIBit)
9. Hiberix
10. Conjugate Vaccines

Best Treatments:
Research Summary Report
on Diphtheria

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.
  • Free Updates for 1 Year
  • All 88 Outcomes
  • Top 200 Key Drugs and Biologics
  • Top 50 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Reference Details
  • Sample PDF Report on Psoriasis >>
Price:$24.00 & Delivery via PDF download
updates for 1 year
Research Interface

 

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.
  • Unlimited Disease, Drug and Therapy Search
  • 2 clicks from Disease to Drug to Evidence
  • Trial References
  • All the Positive Outcomes
  • Detailed Relationship Timeline Charts
  • Full Article Reference Details
  • Includes Mobile Interface Subscription
  • One-click to FDA Products/Patents
  • Request Institution License Details >>
Price:$490.00 access via web interface
1 year subscription
Proceed to Checkout >>
Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.
  • Access from any web enabled PDA or Phone
  • Trial references
  • All the Positive Outcomes
  • Drug and Therapy searches
  • Full Article Reference Details
  • Try Mobile Interface >>
Price:$45.00 access via "curehunter.com/m"
1 year subscription
Proceed to Checkout >>